Suppr超能文献

一种用于帕金森病的巨噬细胞-纳米酶递送系统。

A macrophage-nanozyme delivery system for Parkinson's disease.

作者信息

Batrakova Elena V, Li Shu, Reynolds Ashley D, Mosley R Lee, Bronich Tatiana K, Kabanov Alexander V, Gendelman Howard E

机构信息

Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.

出版信息

Bioconjug Chem. 2007 Sep-Oct;18(5):1498-506. doi: 10.1021/bc700184b. Epub 2007 Aug 31.

Abstract

Selective delivery of antioxidants to the substantia nigra pars compacta (SNpc) during Parkinson's disease (PD) can potentially attenuate oxidative stress and as such increase survival of dopaminergic neurons. To this end, we developed a bone-marrow-derived macrophage (BMM) system to deliver catalase to PD-affected brain regions in an animal model of human disease. To preclude BMM-mediated enzyme degradation, catalase was packaged into a block ionomer complex with a cationic block copolymer, polyethyleneimine-poly(ethylene glycol) (PEI-PEG). The self-assembled catalase/PEI-PEG complexes, "nanozymes", were ca. 60 to 100 nm in size, stable in pH and ionic strength, and retained antioxidant activities. Cytotoxicity was negligible over a range of physiologic nanozyme concentrations. Nanozyme particles were rapidly, 40-60 min, taken up by BMM, retained catalytic activity, and released in active form for greater than 24 h. In contrast, "naked" catalase was rapidly degraded. The released enzyme decomposed microglial hydrogen peroxide following nitrated alpha-synuclein or tumor necrosis factor alpha activation. Following adoptive transfer of nanozyme-loaded BMM to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-intoxicated mice, ca. 0.6% of the injected dose were found in brain. We conclude that cell-mediated delivery of nanozymes can reduce oxidative stress in laboratory and animal models of PD.

摘要

在帕金森病(PD)期间将抗氧化剂选择性递送至黑质致密部(SNpc)可能会减轻氧化应激,从而增加多巴胺能神经元的存活率。为此,我们开发了一种骨髓来源的巨噬细胞(BMM)系统,用于在人类疾病的动物模型中将过氧化氢酶递送至受PD影响的脑区。为了防止BMM介导的酶降解,将过氧化氢酶包装在与阳离子嵌段共聚物聚乙烯亚胺-聚(乙二醇)(PEI-PEG)形成的嵌段离聚物复合物中。自组装的过氧化氢酶/PEI-PEG复合物,即“纳米酶”,尺寸约为60至100nm,在pH和离子强度方面稳定,并保留抗氧化活性。在一系列生理纳米酶浓度范围内,细胞毒性可忽略不计。纳米酶颗粒在40-60分钟内迅速被BMM摄取,保留催化活性,并以活性形式释放超过24小时。相比之下,“裸露的”过氧化氢酶迅速降解。释放的酶在硝化α-突触核蛋白或肿瘤坏死因子α激活后分解小胶质细胞过氧化氢。将负载纳米酶的BMM过继转移至1-甲基-4-苯基-1,2,3,6-四氢吡啶中毒的小鼠后,在脑中发现约0.6%的注射剂量。我们得出结论,细胞介导的纳米酶递送可以在PD的实验室和动物模型中降低氧化应激。

相似文献

1
A macrophage-nanozyme delivery system for Parkinson's disease.
Bioconjug Chem. 2007 Sep-Oct;18(5):1498-506. doi: 10.1021/bc700184b. Epub 2007 Aug 31.
2
Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease.
Nanomedicine (Lond). 2010 Apr;5(3):379-96. doi: 10.2217/nnm.10.7.
3
Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles.
Nanomedicine (Lond). 2011 Jan;6(1):25-42. doi: 10.2217/nnm.10.129.
5
Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins.
Nanomedicine (Lond). 2014 Jul;9(9):1403-22. doi: 10.2217/nnm.13.115. Epub 2013 Nov 18.
6
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6145-50. doi: 10.1073/pnas.0937239100. Epub 2003 Apr 29.
7
Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.
Nanomedicine (Lond). 2011 Sep;6(7):1215-30. doi: 10.2217/nnm.11.32. Epub 2011 Mar 31.
8
Blood-borne macrophage-neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery.
Nanomedicine (Lond). 2012 Jun;7(6):815-33. doi: 10.2217/nnm.11.156. Epub 2012 Jan 11.
10
Exosomes as drug delivery vehicles for Parkinson's disease therapy.
J Control Release. 2015 Jun 10;207:18-30. doi: 10.1016/j.jconrel.2015.03.033. Epub 2015 Mar 31.

引用本文的文献

2
Nanozymes expanding the boundaries of biocatalysis.
Nat Commun. 2025 Jul 24;16(1):6817. doi: 10.1038/s41467-025-62063-8.
4
Navigating the nano-bio immune interface: advancements and challenges in CNS nanotherapeutics.
Front Immunol. 2024 Nov 12;15:1447567. doi: 10.3389/fimmu.2024.1447567. eCollection 2024.
5
Advances in drug delivery systems utilizing blood cells and their membrane-derived microvesicles.
Drug Deliv. 2024 Dec;31(1):2425156. doi: 10.1080/10717544.2024.2425156. Epub 2024 Nov 8.
6
Macrophage based drug delivery: Key challenges and strategies.
Bioact Mater. 2024 Apr 23;38:55-72. doi: 10.1016/j.bioactmat.2024.04.004. eCollection 2024 Aug.
7
Harnessing Microbial Effectors for Macrophage-Mediated Drug Delivery.
ACS Omega. 2024 Apr 11;9(16):18260-18272. doi: 10.1021/acsomega.3c10519. eCollection 2024 Apr 23.
8
Immune cells: potential carriers or agents for drug delivery to the central nervous system.
Mil Med Res. 2024 Mar 29;11(1):19. doi: 10.1186/s40779-024-00521-y.
9
Cell-derived biomimetic nanoparticles for the targeted therapy of ALI/ARDS.
Drug Deliv Transl Res. 2024 Jun;14(6):1432-1457. doi: 10.1007/s13346-023-01494-6. Epub 2023 Dec 20.
10
In situ cellular hitchhiking of nanoparticles for drug delivery.
Adv Drug Deliv Rev. 2024 Jan;204:115143. doi: 10.1016/j.addr.2023.115143. Epub 2023 Nov 24.

本文引用的文献

1
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.
Clin Neurosci Res. 2006 Dec 6;6(5):261-281. doi: 10.1016/j.cnr.2006.09.006.
4
Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery.
J Leukoc Biol. 2006 Nov;80(5):1165-74. doi: 10.1189/jlb.0206110. Epub 2006 Aug 14.
5
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.
Blood. 2006 Oct 15;108(8):2827-35. doi: 10.1182/blood-2006-03-012534. Epub 2006 Jun 29.
7
Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases.
Neurotox Res. 2005 Oct;8(1-2):25-50. doi: 10.1007/BF03033818.
9
Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs.
J Control Release. 2005 Sep 20;107(1):143-57. doi: 10.1016/j.jconrel.2005.06.002.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验